Literature DB >> 11749073

Overexpression of A3 adenosine receptors in smooth, cardiac, and skeletal muscle is lethal to embryos.

Zhihui Zhao1, Ron Yaar, Dan Ladd, Leah M Cataldo, Katya Ravid.   

Abstract

The profile of expression of the A3 adenosine receptor (A3AR) and its importance during embryo development were explored. To this end, different ages of mouse embryos (8.5 days and older) were subjected to in situ hybridization with an A3AR riboprobe. No expression was found in any embryonic tissue except for the aorta and heart of 15.5-day embryos. To investigate further the role of the A3AR gene in development, we overexpressed this gene in A3AR knockout and wild-type mice by using the SM22 alpha promoter. This promoter is active in smooth, cardiac, and skeletal muscle lineages during early embryogenesis (at 8.5 days or earlier), becoming restricted to vascular and visceral smooth muscle cells in late fetal development and adult mice. We observed that moderate copy number incorporation (four copies) of the A3AR gene driven by the SM22 alpha promoter is sufficient to induce lethality at an early stage of embryo development. Remains of 8.5-day transgenic embryos were collected, including fragmented DNA. Hence, we speculate that A3AR homeostasis is critical for embryo viability and proper development. This finding is intriguing in view of the reported effects of sustained activation of the A3AR on induction of DNA fragmentation and apoptosis in cultured myocytes and other cell types.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11749073     DOI: 10.1006/mvre.2001.2366

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  10 in total

Review 1.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

2.  Internalization and desensitization of adenosine receptors.

Authors:  Elisabeth C Klaasse; Adriaan P Ijzerman; Willem J de Grip; Margot W Beukers
Journal:  Purinergic Signal       Date:  2007-11-13       Impact factor: 3.765

Review 3.  Regulation of cardiovascular development by adenosine and adenosine-mediated embryo protection.

Authors:  Scott A Rivkees; Christopher C Wendler
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

4.  Comparative genomic and expression analysis of the adenosine signaling pathway members in Xenopus.

Authors:  Alice Tocco; Benoît Pinson; Pierre Thiébaud; Nadine Thézé; Karine Massé
Journal:  Purinergic Signal       Date:  2014-10-16       Impact factor: 3.765

Review 5.  Adenosine and protection from acute kidney injury.

Authors:  Steven C Yap; H Thomas Lee
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-01       Impact factor: 2.894

6.  Pharmacological and molecular characterization of functional P2 receptors in rat embryonic cardiomyocytes.

Authors:  Kwok-Kuen Cheung; Camila Marques-da-Silva; Leandro Vairo; Danúbia Silva dos Santos; Regina Goldenberg; Robson Coutinho-Silva; Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2014-12-16       Impact factor: 3.765

7.  Adenosine A(3) receptors regulate heart rate, motor activity and body temperature.

Authors:  J N Yang; Y Wang; P M Garcia-Roves; M Björnholm; B B Fredholm
Journal:  Acta Physiol (Oxf)       Date:  2010-02-01       Impact factor: 6.311

Review 8.  Adenosine receptors and renal ischaemia reperfusion injury.

Authors:  M M Rabadi; H T Lee
Journal:  Acta Physiol (Oxf)       Date:  2014-10-27       Impact factor: 6.311

9.  Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain.

Authors:  Silvia Paoletta; Dilip K Tosh; Amanda Finley; Elizabeth T Gizewski; Steven M Moss; Zhan-Guo Gao; John A Auchampach; Daniela Salvemini; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2013-07-03       Impact factor: 7.446

Review 10.  Purines as potential morphogens during embryonic development.

Authors:  Karine Massé; Nicholas Dale
Journal:  Purinergic Signal       Date:  2012-01-25       Impact factor: 3.765

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.